Biomaterial Database

Malignant fibrous histiocytoma: the most common soft-tissue sarcoma. 1988

A R Makepeace, and S R Cannon

Middlesex Hospital, London.

Although soft-tissue sarcomas account for less than 1% of all malignancies, over 55 different histological variants have been described. Consequently clinicians often find the classification both complex and confusing. A new variant, the malignant fibrous histiocytoma (MFH), is now the most common adult soft-tissue sarcoma, therefore a clear understanding of the diagnosis, its implications and the optimum treatment is desirable.

UI	MeSH Term	Description	Entries
D003131	Combined Modality Therapy	The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.	Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000971	Antineoplastic Combined Chemotherapy Protocols	The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.	Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D012509	Sarcoma	A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	Sarcoma, Epithelioid,Sarcoma, Soft Tissue,Sarcoma, Spindle Cell,Epithelioid Sarcoma,Epithelioid Sarcomas,Sarcomas,Sarcomas, Epithelioid,Sarcomas, Soft Tissue,Sarcomas, Spindle Cell,Soft Tissue Sarcoma,Soft Tissue Sarcomas,Spindle Cell Sarcoma,Spindle Cell Sarcomas
D012983	Soft Tissue Neoplasms	Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.	Neoplasm, Soft Tissue,Neoplasms, Soft Tissue,Soft Tissue Neoplasm
D018219	Histiocytoma, Benign Fibrous	A benign tumor composed, wholly or in part, of cells with the morphologic characteristics of HISTIOCYTES and with various fibroblastic components. Fibrous histiocytomas can occur anywhere in the body. When they occur in the skin, they are called dermatofibromas or sclerosing hemangiomas. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 5th ed, p1747)	Dermatofibroma,Hemangioma, Sclerosing,Histiocytoma, Cutaneous,Histiocytoma, Fibrous,Angioma, Sclerosing,Benign Fibrous Histiocytoma,Angiomas, Sclerosing,Benign Fibrous Histiocytomas,Cutaneous Histiocytoma,Cutaneous Histiocytomas,Dermatofibromas,Fibrous Histiocytoma,Fibrous Histiocytoma, Benign,Fibrous Histiocytomas,Fibrous Histiocytomas, Benign,Hemangiomas, Sclerosing,Histiocytomas, Benign Fibrous,Histiocytomas, Cutaneous,Histiocytomas, Fibrous,Sclerosing Angioma,Sclerosing Angiomas,Sclerosing Hemangioma,Sclerosing Hemangiomas